Free Trial

Natera Q1 2023 Earnings Report

Natera logo
$158.36 -10.14 (-6.02%)
As of 01/17/2025 04:00 PM Eastern

Natera EPS Results

Actual EPS
-$1.23
Consensus EPS
-$1.18
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$1.45

Natera Revenue Results

Actual Revenue
$241.76 million
Expected Revenue
$227.43 million
Beat/Miss
Beat by +$14.33 million
YoY Revenue Growth
+24.50%

Natera Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

Natera Earnings Headlines

Natera’s Strategic Advancements and Market Positioning Drive Buy Rating
Natera price target raised to $200 from $170 at Guggenheim
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Natera’s Strong Market Position and Growth Potential Drive Buy Rating
See More Natera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Natera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Natera and other key companies, straight to your email.

About Natera

Natera (NASDAQ:NTRA), a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

View Natera Profile

More Earnings Resources from MarketBeat